Clinical study of recombinant human endostatin with GP regimen in the treatment of advanced non-small-cell lung cancer

VernacularTitle:重组人血管内皮抑制素联合GP方案治疗晚期非小细胞肺癌
Author: Ming GU ; Limin GENG ; Hongyi SUN
Publication Type:Journal Article
Keywords: Carcinoma; non-small-cell lung; Angiostatins; Drug therapy,combination
From: Cancer Research and Clinic 2011;23(10):690-692
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and security of combined recombinant human endostatin with GP chemotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC).Methods Non- randomized concurrent control was used.32 patients were treated by recombinant human endostatin combined with chemotherapy as test group,40 patients of control group only received chemotherapy.The response rate (RR),the clinical benefit rate (CBR) and the time to progression (TTP) were observed.Results The total RR in two groups were 40.6 ％ and 20.0 ％ (x2 =3.66,P =0.07).The total CBR were 68.8 ％ and 42.5 ％ (x2 =4.93,P =0.034).The total time to progression were 5.2 months and 3.9 months (P =0.042).Incidence of adverse reactions of experimental group and control group was no significant difference.Conclusion Combined recombinant human endostatin and chemotherapy can improve the curative effect (RR,CBR and TTP) of advanced NSCLC.